CETP inhibition in cardiovascular risk management: a critical appraisal. - Wikidata - wikimedia - TriplyDB

CETP inhibition in cardiovascular risk management: a critical appraisal.

CETP inhibition in cardiovascular risk management: a critical appraisal.

http://www.wikidata.org/entity/Q36705260

about

Crystal Structures of Cholesteryl Ester Transfer Protein in Complex with Inhibitors Low-normal thyroid function and novel cardiometabolic biomarkers Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease A reduction of CETP activity, not an increase, is associated with modestly impaired postprandial lipemia and increased HDL-cholesterol in adult asymptomatic women How can we prevent cardiovascular disease in diabetes.The importance of treating cardiometabolic risk factors in patients with type 2 diabetes.Viability of developing CETP inhibitors.Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis.Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.Low-normal thyroid function and the pathogenesis of common cardio-metabolic disorders.Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.Dietary calcium decreases plasma cholesterol by down-regulation of intestinal Niemann-Pick C1 like 1 and microsomal triacylglycerol transport protein and up-regulation of CYP7A1 and ABCG 5/8 in hamsters.

P2860

Q27672820-94193824-DE90-4880-97FC-7D3AAFA53A73 Q28084990-402FDAA6-4D85-4B52-81E4-BBEB07DBD2C2 Q33901943-1AB91894-F65A-4A3A-8E9A-6BED939878F0 Q35074336-093AE97C-C01F-4E05-83DE-6C7E1769983B Q36889170-85E54499-18B3-46C1-9428-4F10DBE42182 Q37132923-5E1A0512-7DF6-46E6-BFF7-F31FCEF31C92 Q37165682-1708FFD3-0A2E-4255-B8D1-BDC1C9436611 Q37179542-C12553D4-AC85-47B0-9116-4E95E9414A22 Q37382142-F4CDC9F9-AE75-466B-B54A-AF6AE94DA38E Q37707402-F4460CC4-E3EB-4005-9924-20254CF8C5C2 Q37774393-0D6BB97E-2A80-4B36-B835-B10AC8A03C00 Q38359090-3AA55853-01AD-4E06-956A-AE125A8FF19F Q45978355-202792A6-48A0-4E55-9004-B351C2E19146 Q51772227-5A2EDEED-7E9A-4EA0-B065-4139ABB1BBB1

P2860

CETP inhibition in cardiovascular risk management: a critical appraisal.

http://www.wikidata.org/entity/Q36705260

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

CETP inhibition in cardiovascular risk management: a critical appraisal.

@ast

CETP inhibition in cardiovascular risk management: a critical appraisal.

@en

type

label

CETP inhibition in cardiovascular risk management: a critical appraisal.

@ast

CETP inhibition in cardiovascular risk management: a critical appraisal.

@en

prefLabel

CETP inhibition in cardiovascular risk management: a critical appraisal.

@ast

CETP inhibition in cardiovascular risk management: a critical appraisal.

@en

P1433

Q36705260-FB89FDBB-BE90-4345-9E8F-D5D6EA8BE0A8

P1476

Q36705260-85651664-0F8F-4782-AF3E-1CA7CEA6BC7A

P2093

Q36705260-1DEE8FED-2100-4912-AF76-B42A77B4BE06

Q36705260-3F32F82B-733B-43AD-84F5-DF31D7487389

Q36705260-6C45F826-6C7A-4804-A70B-B34794E3F378

Q36705260-EBCFA043-A6E2-4CBE-960E-167453C82FEE

P2860

Q36705260-02A4185C-234B-4145-8830-9FC5AD140E86

Q36705260-041BDE01-218B-4210-8302-C632F1F4808B

Q36705260-09A31E73-81D6-4E70-9FDD-D90F18F3038B

Q36705260-147E733B-7922-45B2-855B-89CFCBDEB5CE

Q36705260-195D2ACB-159D-4798-9897-12C7C2893873

Q36705260-1E2F19FB-832F-4427-90F2-E26687717F8D

Q36705260-2A7F8B65-B556-4690-A2EA-3FA6801357A1

Q36705260-2ACB8B4E-3D49-4FAB-BE4C-65555C0ACF32

Q36705260-2DE7BB44-D947-4487-ADE8-F0D0E4F37464

Q36705260-30441A4A-4243-448C-8738-BBDD07177150

P304

Q36705260-D5DAC23F-1660-4415-8E67-F6937A3F02F7

P31

Q36705260-ED0806CC-50F2-4672-B053-30728E1DC5FA

P356

Q36705260-2095D0B2-7D50-43E4-BEFD-CCCAFE2AE345

P433

Q36705260-6A0AC252-08BF-486B-8333-8DB1E6DEE265

P478

Q36705260-4CD5CD88-2136-4EA3-80E7-031A629B8F6C

P577

Q36705260-33B79D2F-2197-4B41-9AC5-56FFA5F07026

P5875

Q36705260-4280F562-D65B-4DC5-B4F5-B6BDD5D9EBF7

P698

Q36705260-D2AAD7E0-8FB3-42D6-B383-C236E43AEA76

P356

J.1365-2362.2007.01756.X

P1433

European Journal of Clinical Investigation

P1476

CETP inhibition in cardiovascular risk management: a critical appraisal.

@en

P2093

Dallinga-Thie GM

http://www.w3.org/2001/XMLSchema#string

Dullaart RP

http://www.w3.org/2001/XMLSchema#string

Wolffenbuttel BH

http://www.w3.org/2001/XMLSchema#string

van Tol A

http://www.w3.org/2001/XMLSchema#string

P2860

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action

Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia.

Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein.

P304

90-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2362.2007.01756.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6584935

http://www.w3.org/2001/XMLSchema#string

P698

17217373

http://www.w3.org/2001/XMLSchema#string